Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ultragenyx Pharmaceutical Inc    RARE

ULTRAGENYX PHARMACEUTICAL INC (RARE)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
Most relevant news about ULTRAGENYX PHARMACEUTICAL
10/09FDA, EMA to review Novartis' siponimod for secondary progressive MS
AQ
10/01ULTRAGENYX PHARMACEUTICAL : to Present at Jefferies Gene Therapy Summit
AQ
09/27Ultragenyx Announces Positive Topline Cohort 2 Results from Phase 1/2 Clinica..
GL
09/26ULTRAGENYX PHARMACEUTICAL : to Present at Jefferies Gene Therapy Summit
AQ
09/19ULTRAGENYX PHARMACEUTICAL : Expands Leadership Team and Appoints Dr. Wladimir Ho..
AQ
09/17Ultragenyx Expands Leadership Team and Appoints Dr. Wladimir Hogenhuis as Chi..
GL
08/30Ultragenyx to Present at Upcoming Investor Conferences
GL
08/30ULTRAGENYX PHARMACEUTICAL : FDA clarifies path to submission for Ultragenyx's ra..
AQ
08/29ULTRAGENYX PHARMACEUTICAL : Announces FDA Accepts Proposal to Submit an NDA for ..
AQ
08/28ULTRAGENYX PHARMACEUTICAL : Announces Approval of Mepsevii in Europe for the Tre..
AQ
08/27Ultragenyx Announces Approval of Mepsevii™ (vestronidase alfa) in Europ..
GL
08/03ULTRAGENYX : 2Q Earnings Snapshot
AQ
08/02Ultragenyx Reports Second Quarter 2018 Financial Results and Corporate Update
GL
07/31ULTRAGENYX PHARMACEUTICAL : to Host Conference Call for Second Quarter 2018 Fina..
AQ
07/27Ultragenyx to Host Conference Call for Second Quarter 2018 Financial Results ..
GL
07/26ULTRAGENYX PHARMACEUTICAL : Announces First Patient Dosed in Phase 1/2 study of ..
AQ
07/04ULTRAGENYX PHARMACEUTICAL : Announces Positive CHMP Opinion for Mepsevii for the..
AQ
06/29Ultragenyx Announces Positive CHMP Opinion for Mepsevii™ (vestronidase ..
GL
06/04ULTRAGENYX PHARMACEUTICAL : to Present at Upcoming Investor Conferences
AQ
05/24Ultragenyx and Kyowa Kirin Announce Publication of Phase 2 Study Results Demo..
AQ
05/23Ultragenyx and Kyowa Kirin Announce Publication of Phase 2 Study Results Demo..
GL
05/22Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results
AQ
05/21Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrati..
AQ
05/17Ultragenyx and Kyowa Kirin Announce Topline Phase 3 Study Results Demonstrati..
GL
05/11Ultragenyx and Kyowa Kirin Announce Crysvita Now Launched in the U.S. for the..
AQ
05/11ULTRAGENYX PHARMACEUTICAL : Reports First Quarter 2018 Financial Results and Cor..
AQ
05/07ULTRAGENYX : 1Q Earnings Snapshot
AQ
05/07Ultragenyx Reports First Quarter 2018 Financial Results and Corporate Update
GL
05/04ULTRAGENYX PHARMACEUTICAL : to Host Conference Call for First Quarter 2018 Finan..
AQ
05/03Ultragenyx and Kyowa Kirin Announce Crysvita Now Launched in the U.S. for the..
AQ
05/01Ultragenyx to Host Conference Call for First Quarter 2018 Financial Results a..
GL
04/30Ultragenyx and Kyowa Kirin Announce Crysvita® (burosumab-twza) Now Launched i..
GL
04/23Ultragenyx Announces Filing and FDA Clearance of an Investigational New Drug ..
GL
04/17Ultragenyx and Kyowa Kirin Announce FDA Approval of Crysvita® (burosumab-twza..
GL
03/08Ultragenyx to Present at Upcoming Investor Conferences
GL
03/07ULTRAGENYX PHARMACEUTICAL : Announces Positive Topline Results and DMC Review fr..
AQ
02/26Kyowa Kirin and Ultragenyx Announce Crysvita Receives Conditional Marketing A..
AQ
02/26XLH therapy burosumab gains EU approval
AQ
02/23Kyowa Kirin and Ultragenyx Announce Crysvita® (burosumab) Receives Conditiona..
GL
02/20ULTRAGENYX PHARMACEUTICAL : reports 4Q loss
AQ
02/20Ultragenyx Reports Fourth Quarter and Full Year 2017 Financial Results and Co..
GL
02/16ULTRAGENYX PHARMACEUTICAL : to Host Conference Call for Fourth Quarter and Full ..
AQ
02/14ULTRAGENYX PHARMACEUTICAL : to Host Conference Call for Fourth Quarter and Full ..
PU
02/14Ultragenyx to Host Conference Call for Fourth Quarter and Full Year 2017 Fin..
GL
02/08Ultragenyx to Present at Leerink Partners Global Healthcare Conference
GL
02/01ULTRAGENYX PHARMACEUTICAL : Appoints Camille L. Bedrosian, M.D. as Chief Medical..
AQ
01/29Ultragenyx Appoints Camille L. Bedrosian, M.D. as Chief Medical Officer and E..
GL
01/24Ultragenyx Announces Pricing of Public Offering of Common Stock
GL
01/22Ultragenyx Announces Proposed Public Offering of Common Stock
GL
01/08NEWMAN FERRARA LLP : Announces Corporate Governance Investigation of Ultragenyx ..
BU
01/07ULTRAGENYX PHARMACEUTICAL : Announces Positive Interim Topline Results From Firs..
PU
01/07Ultragenyx Announces Positive Interim Topline Results From First Cohort of Ph..
GL
01/04Ultragenyx Announces Update to UX007 Development Program in Long-Chain Fatty ..
GL
01/04Ultragenyx to Present at J.P. Morgan Healthcare Conference
GL
2017ULTRAGENYX PHARMACEUTICAL : Sells Priority Review Voucher for $130 million
AQ
2017Ultragenyx and Kyowa Kirin Announce Burosumab Receives Positive CHMP Opinion ..
AQ
2017ULTRAGENYX PHARMACEUTICAL : Novartis buying Ultragenyx's Priority Review voucher
AQ
2017Ultragenyx Sells Priority Review Voucher for $130 million
GL
2017Ultragenyx and Kyowa Kirin Announce Burosumab Receives Positive CHMP Opinion ..
GL
2017Ultragenyx and Kyowa Kirin Announce Positive 48-Week Data from Adult Phase 3 ..
AQ
2017Ultragenyx and Kyowa Kirin Announce Positive 48-Week Data from Adult Phase 3 ..
GL
2017Ultragenyx to Highlight Pipeline at Analyst and Investor Day on December 4
GL
2017ULTRAGENYX PHARMACEUTICAL : Announces FDA Approval of MEPSEVII the First Therapy..
AQ
2017Ultragenyx Announces Completion of Patient Dosing in First Cohort of Phase 1/..
GL
2017Ultragenyx Announces FDA Approval of MEPSEVII™ (vestronidase alfa), the..
GL
2017ULTRAGENYX PHARMACEUTICAL : Completes Tender Offer and Acquisition of Dimension ..
AQ
2017Ultragenyx Completes Tender Offer and Acquisition of Dimension Therapeutics
GL
2017Ultragenyx to Present at the Credit Suisse Healthcare Conference
GL
2017ULTRAGENYX PHARMACEUTICAL : reports 3Q loss
AQ
2017Ultragenyx and Kyowa Hakko Kirin Announce FDA Not Currently Planning to Hold ..
AQ
2017Ultragenyx Reports Third Quarter 2017 Financial Results and Corporate Update
GL
2017Ultragenyx and Kyowa Hakko Kirin Announce FDA Not Currently Planning to Hold ..
GL
2017Ultragenyx to Host Conference Call for Third Quarter 2017 Financial Results a..
GL
2017ULTRAGENYX PHARMACEUTICAL : and Dimension Announce Expiration of Hart Scott Rodi..
AQ
2017ULTRAGENYX PHARMACEUTICAL : and Dimension Announce Expiration of Hart-Scott-Rodi..
PU
1  2  3Next
Financials ($)
Sales 2018 56,1 M
EBIT 2018 -390 M
Net income 2018 -227 M
Finance 2018 255 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 53,3x
EV / Sales 2019 28,1x
Capitalization 3 249 M
Chart ULTRAGENYX PHARMACEUTICAL INC
Duration : Period :
Ultragenyx Pharmaceutical Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ULTRAGENYX PHARMACEUTICAL
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 84,8 $
Spread / Average Target 28%
EPS Revisions
Managers
NameTitle
Emil D. Kakkis President, Chief Executive Officer & Director
Daniel G. Welch Non-Executive Chairman
Wladimir Hogenhuis Chief Operating Officer
Shalini Sharp Chief Financial Officer & Executive Vice President
Dennis Karl Huang Chief Technical Operations Officer & Senior VP
Sector and Competitors
1st jan.Capitalization (M$)
ULTRAGENYX PHARMACEUTICAL INC33.23%3 249
GILEAD SCIENCES1.59%95 398
VERTEX PHARMACEUTICALS20.99%46 338
REGENERON PHARMACEUTICALS2.18%40 777
NEUROCRINE BIOSCIENCES, INC.41.84%10 086
SAREPTA THERAPEUTICS INC136.05%8 671